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Abstract
Background: Clinical trial registries may allow for producing a global mapping of health research. However, health
conditions are not described with standardized taxonomies in registries. Previous work analyzed clinical trial
registries to improve the retrieval of relevant clinical trials for patients. However, no previous work has classified
clinical trials across diseases using a standardized taxonomy allowing a comparison between global health research and
global burden across diseases. We developed a knowledge-based classifier of health conditions studied in registered
clinical trials towards categories of diseases and injuries from the Global Burden of Diseases (GBD) 2010 study.
The classifier relies on the UMLS® knowledge source (Unified Medical Language System®) and on heuristic algorithms for
parsing data. It maps trial records to a 28-class grouping of the GBD categories by automatically extracting UMLS
concepts from text fields and by projecting concepts between medical terminologies. The classifier allows deriving
pathways between the clinical trial record and candidate GBD categories using natural language processing and links
between knowledge sources, and selects the relevant GBD classification based on rules of prioritization across the
pathways found. We compared automatic and manual classifications for an external test set of 2,763 trials. We
automatically classified 109,603 interventional trials registered before February 2014 at WHO ICTRP.
Results: In the external test set, the classifier identified the exact GBD categories for 78 % of the trials. It had very good
performance for most of the 28 categories, especially “Neoplasms” (sensitivity 97.4 %, specificity 97.5 %). The sensitivity
was moderate for trials not relevant to any GBD category (53 %) and low for trials of injuries (16 %). For the 109,603 trials
registered at WHO ICTRP, the classifier did not assign any GBD category to 20.5 % of trials while the most common GBD
categories were “Neoplasms” (22.8 %) and “Diabetes” (8.9 %).
Conclusions: We developed and validated a knowledge-based classifier allowing for automatically identifying the
diseases studied in registered trials by using the taxonomy from the GBD 2010 study. This tool is freely available to the
research community and can be used for large-scale public health studies.
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Background
The World Health Organization (WHO) has indicated the
pressing need for a comprehensive monitoring of health
research and development (R&D) to coordinate limited
resources towards reducing the gaps between health
research and health needs [1–3]. Mapping the global
landscape of health R&D will allow for identifying diseases
for which there is too much or too little research at a local
level as compared to their burden at the same level [4].
The WHO is developing the Global Observatory on
Health R&D and aims at analyzing multiple data sources
to quantify the global state of health R&D, including clin-
ical trial registries, publications, product pipelines, patents
and grants [3, 5].
Although concerning a particular type of health R&D
activity, one source of data, clinical trial registries, is
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readily available and could be used to rapidly achieve a
global mapping [6]. Worldwide, clinical trials are regis-
tered in publicly accessible repositories with a common
structure of data fields [7]. The WHO gathers 16 regis-
tries in the International Clinical Trials Registry Plat-
form (ICTRP), now the largest repository of clinical
trials worldwide [8].
However, the diseases studied by clinical trials regis-
tered in the WHO ICTRP are not described in trial re-
cords by using a standardized taxonomy but rather as
free text with considerable heterogeneity. With more
than 300,000 clinical trial records in the WHO ICTRP
and more than 20,000 new records registered every year,
the use of automatic methods for classification is im-
perative [8, 9]. Natural Language Processing (NLP) al-
lows clinical knowledge representation in standardized
formats and is becoming mature enough to be used effi-
ciently for targeted applications [10, 11]. In particular,
NLP methods have been developed to face the limita-
tions of the retrieval systems of clinical trial registries
such as clinicaltrials.gov. [12, 13] For instance, clinical
trial records have been notably analyzed using NLP to
provide formal representations of eligibility criteria, or to
enrich eligibility criteria with meta-data to improve the re-
trieval of relevant clinical trials for patients [14–26]. How-
ever, none of these studies have analyzed the performance
of retrieval of clinical trials across diseases, but rather
across features of eligibility criteria (e.g. age, BMI 1 or
more complex features) for specific diseases.
Moreover, the health conditions studied in registered
clinical trials must be classified by using a taxonomy of
diseases that allows for comparisons between the num-
bers of clinical trials and the actual burden of diseases.
A consensual taxonomy over which the evolution of the
burden is estimated regionally was developed by the US
Institute for Health Metrics and Evaluation for the
Global Burden of Diseases (GBD) 2010 study [27, 28].
Previous studies have developed NLP methods to index
clinical trial records using Medical Subject Headings
(MeSH) [29], and to regroup clinical trials across med-
ical specialties [30]. However, to our knowledge no pre-
vious work has classified clinical trials using a taxonomy
allowing a comparison between global health research
and global burden across diseases.
Objective
We aimed to develop and validate a method that auto-
matically maps the health conditions studied in regis-
tered clinical trials to the taxonomy from the GBD 2010
study. Towards that goal, we relied on Natural Language
Processing to analyze the free-text description of health
conditions found in clinical trial records, and a standard-
ized knowledge representation of diseases to encode the
information extracted from the trial records.
Methods
We developed a knowledge-based classifier allowing for
automatic mapping of the health conditions studied in
registered clinical trials to a 28- and 171-class grouping
of the taxonomy of diseases and injuries defined by the
GBD 2010 study. Our approach did not rely on statis-
tical classification techniques but instead relied on text
analysis and exploited the Unified Medical Language
System® (UMLS®) as a domain knowledge resource. Spe-
cifically, the classification is based on the recognition of
medical concepts in the free text description of trials
and the mapping of concepts between medical taxon-
omies. The classifier allows deriving pathways between
the clinical trial record and the taxonomy of diseases
and injuries from the GBD study based on a succession
of mathematical projections (also called normalization
or entity linking). Finally, the classifier selects the rele-
vant GBD classification based on rules of prioritization
across the pathways found. We measured the classifier
performance by comparing the automatic classifications
to manual classifications with a large test set of regis-
tered clinical trials. Finally, we used the classifier to map
the conditions studied by all trials registered at the
WHO ICTRP.
From clinical trial records to the GBD cause list
GBD cause list
The GBD cause list is a set of 291 mutually exclusive
and collectively exhaustive categories of diseases and
injuries [28]. Each category is defined in terms of the
codes of the International Classification of Diseases
9th and 10th versions (ICD9 and ICD10) [31]. We
used the mapping from the ICD10 to the GBD cause
list (Web Table 3 in [27]). Several residual categories,
such as “Other infectious diseases”, are made up of
ill-defined or residual causes from major disease
groups. We excluded these because they are not in-
formative from the perspective of a global analysis of
the burden of diseases.
We developed a smaller list of categories by using a for-
mal consensus method. Six experts independently defined
a higher-level grouping of diseases and injuries that are
sufficiently informative for developing a global mapping of
clinical trials across health needs. The resulting list con-
tained 28 categories that accounted for 98.8 % of the glo-
bal burden in 2010 (Table 1). Moreover, we considered the
list of aggregated categories defined by the GBD 2010
study to inform policy makers on the main health prob-
lems per country (Web Table 1 in [28]). This grouping
contained 171 GBD categories that accounted for 90.6 %
of the global burden of disease in 2010 (Additional file 1:
Table S1). We report results of the mapping to the 28 cat-
egories; results of the mapping to the 171 categories are
presented in the Additional file 1.
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Table 1 Grouping of the Global Burden of Diseases (GBD) cause list in 28 GBD categories
GBD categories Partition of the GBD cause list
Tuberculosis Tuberculosis
HIV/AIDS HIV/AIDS
Diarrhea, lower respiratory infections, meningitis, and
other common infectious diseases
Diarrheal diseases; Typhoid and paratyphoid fevers; Lower respiratory infections; Upper
respiratory infections; Otitis media: Meningitis; Encephalitis; Diphtheria; Whooping cough;
Tetanus; Measles; Varicella
Malaria Malaria
Neglected tropical diseases excluding malaria Chagas disease; Leishmaniasis: African trypanosomiasis; Schistosomiasis; Cysticercosis;
Echinococcosis; Lymphatic filariasis; Onchocerciasis; Trachoma; Dengue; Yellow fever; Rabies;
Food-borne trematodiases; Intestinal nematode infections; Other neglected tropical diseases
Maternal disorders Maternal hemorrhage; Maternal sepsis; Hypertensive disorders of pregnancy; Obstructed
labor; Abortion; Other maternal disorders
Neonatal disorders Preterm birth complications; Neonatal encephalopathy (birth asphyxia and birth trauma);
Sepsis and other infectious disorders of the newborn baby; Other neonatal disorders
Nutritional deficiencies Protein-energy malnutrition; Iodine deficiency; Vitamin A deficiency; Iron-deficiency anemia;
Other nutritional deficiencies
Sexually transmitted diseases excluding HIV Syphilis; Sexually transmitted chlamydial diseases; Gonococcal infection; Trichomoniasis;
Other sexually transmitted diseases
Hepatitis Acute hepatitis A; Acute hepatitis B; Acute hepatitis C; Acute hepatitis E
Leprosy Leprosy
Neoplasms Esophageal cancer; Stomach cancer; Liver cancer; Larynx cancer; Trachea, bronchus, and lung
cancers; Breast cancer; Cervical cancer; Uterine cancer; Prostate cancer; Colon and rectum
cancers; Mouth cancer; Nasopharynx cancer; Cancer of other part of pharynx and oropharynx;
Gallbladder and biliary tract cancer; Pancreatic cancer; Malignant melanoma of skin; Non-
melanoma skin cancer; Ovarian cancer; Testicular cancer; Kidney and other urinary organ
cancers; Bladder cancer; Brain and nervous system cancers; Thyroid cancer; Hodgkin's disease;
Non-Hodgkin lymphoma; Multiple myeloma; Leukemia; Other neoplasms
Cardiovascular and circulatory diseases Rheumatic heart disease; Ischemic heart disease; Cerebrovascular disease; Hypertensive heart
disease; Cardiomyopathy and myocarditis; Atrial fibrillation and flutter; Aortic aneurysm;
Peripheral vascular disease; Endocarditis; Other cardiovascular and circulatory diseases
Chronic respiratory diseases Chronic obstructive pulmonary disease; Pneumoconiosis; Asthma; Interstitial lung disease
and pulmonary sarcoidosis; Other chronic respiratory diseases
Cirrhosis of the liver Cirrhosis of the liver
Digestive diseases (except cirrhosis) Peptic ulcer disease; Gastritis and duodenitis; Appendicitis; Paralytic ileus and intestinal
obstruction without hernia; Inguinal or femoral hernia; Non-infective inflammatory bowel
disease; Vascular disorders of intestine; Gall bladder and bile duct disease; Pancreatitis; Other
digestive diseases
Neurological disorders Alzheimer's disease and other dementias; Parkinson's disease; Epilepsy; Multiple sclerosis;
Migraine; Tension-type headache; Other neurological disorders
Mental and behavioral disorders Schizophrenia; Alcohol use disorders; Drug use disorders; Unipolar depressive disorders;
Bipolar affective disorder; Anxiety disorders; Eating disorders; Pervasive development
disorders; Childhood behavioral disorders; Idiopathic intellectual disability; Other mental and
behavioral disorders
Diabetes, urinary diseases and male infertility Diabetes mellitus; Acute glomerulonephritis; Chronic kidney diseases; Urinary diseases and
male infertility
Gynecological diseases Uterine fibroids; Polycystic ovarian syndrome; Female infertility; Endometriosis; Genital
prolapse; Premenstrual syndrome; Other gynecological diseases
Hemoglobinopathies and hemolytic anemias Hemoglobinopathies and hemolytic anemias; Thalassemias; Sickle cell disorders; G6PD
deficiency; Other hemoglobinopathies and hemolytic anemias
Musculoskeletal disorders Rheumatoid arthritis; Osteoarthritis; Low back and neck pain; Gout; Other muskuloskeletal
disorders
Congenital anomalies Congenital anomalies; Neural tube defects; Congenital heart anomalies; Cleft lip and cleft
palate; Down's syndrome; Other chromosomal abnormalities; Other congenital anomalies
Skin and subcutaneous diseases Eczema; Psoriasis; Cellulitis; Abscess, impetigo, and other bacterial skin diseases; Scabies;
Fungal skin diseases; Viral skin diseases; Acne vulgaris; Alopecia areata; Pruritus; Urticaria;
Decubitus ulcer; Other skin and subcutaneous diseases
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Clinical trial records
In the WHO Trial Registration Dataset, the “Health
Condition(s) or Problem(s) studied” field contains a nat-
ural language description of the primary condition or
problem studied in any clinical trial. Figure 1 shows an
example for which the health condition field is “Knee
Osteoarthritis” and “Hip Osteoarthritis”. This description
is not captured by a coded field, with a standardized tax-
onomy of diseases, but is rather described in a free-text
field. Moreover, the analysis of this free-text field alone
may not be sufficient to identify the GBD categories of
interest. Numerous health condition fields are empty, have
entry errors, correspond to “Healthy volunteers”, or the
relevant GBD category may be difficult to identify because
of synonymy. Thus, we also considered the “Public Title”
and “Scientific Title” fields, which are most likely to bring
additional information about the condition studied in the
clinical trial and to enrich the mapping.
Classifier development
Because GBD categories are defined by ICD10 codes, we
aimed to classify the text fields according to ICD10 codes.
Table 1 Grouping of the Global Burden of Diseases (GBD) cause list in 28 GBD categories (Continued)
Sense organ diseases Glaucoma; Cataracts; Macular degeneration; Refraction and accommodation disorders; Other
hearing loss; Other vision loss; Other sense organ diseases
Oral disorders Dental caries; Periodontal disease; Edentulism
Sudden infant death syndrome Sudden infant death syndrome
Injuries Transport injuries; Unintentional injuries other than transport injuries; Self-harm and interpersonal
violence; Forces of nature, war, and legal intervention
Excluded residual categories Other infectious diseases; Other endocrine, nutritional, blood, and immune disorders
Grouping of the cause list of diseases and injuries from the Global Burden of Diseases 2010 study in 28 GBD categories, plus the excluded residual categories. This
grouping was considered sufficiently informative for a global mapping of health research to a global mapping of health needs
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Fig. 1 Example of classification of a clinical trial record towards the GBD categories. The classification process is based on text extraction from the
trial record, text annotation using UMLS concepts, projection of UMLS concepts to ICD10 codes, projection of ICD10 codes to candidate GBD
categories among the 28 GBD categories, and GBD classification based on the candidate GBD categories. In this example, the text annotation
involved use of the WSD server for MetaMap, and no expert-based enrichment was needed
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The Unified Medical Language System® (UMLS®), devel-
oped at the US National Library of Medicine (NLM), is the
most comprehensive metathesaurus to analyze biomedical
text in English to date [32]. We based our classifier on
established methods using the UMLS knowledge source to
automatically annotate trial records with ICD10 codes.
Figure 2 illustrates the 5 methodological stages we de-
fined for the classifier (interactive version at http://clinical
epidemio.fr/gbd_graph). The 4 initial stages allow for deriv-
ing pathways from the clinical trial record to candidate
GBD categories. The 5th stage allows for deriving the GBD
classification based on prioritization rules over the path-
ways found.
Free text annotation with concepts from the unified medical
language system
We first annotated the text fields (health condition, public
title and scientific title) with concepts from the UMLS
metathesaurus [32]. The annotation involved use of Meta-
Map, a tool from the NLM for recognizing UMLS concepts
in text [33]. We considered only UMLS concepts corre-
sponding to diseases or injuries (MetaMap implementation
in Additional file 1). A Word Sense Disambiguation
(WSD) server can be used to select a single UMLS
concept when a text is annotated with several UMLS
concepts. We developed the classifier with and without
using the WSD server. In Fig. 1, the health condition field
was annotated with the concepts “Osteoarthritis, Knee”
(C0409959) and “Osteoarthritis of hip” (C0029410).
Mapping of UMLS concepts to ICD10 codes
Each UMLS concept was then projected to one or several
ICD10 codes. The projection involved a semantic-based ap-
proach to connect different terminologies present in the
UMLS database, namely the Restrict-to-ICD10 algorithm, as
implemented in the IntraMap program (IntraMap imple-
mentation in Additional file 1) [34]. In the example from
Fig. 1, the concept “Osteoarthritis, Knee” was projected
to the ICD10 codes “Coxarthrosis [arthrosis of hip]” and
“Coxarthrosis, unspecified”.
Mapping of ICD10 codes to candidate GBD categories
The resulting ICD10 codes were then projected to one
or several candidate GBD categories. ICD10 codes could
correspond to three- and four-character ICD10 codes
(e.g. M16 and M16.9 in the example from Fig. 1), or to
blocks of three- and four-character ICD10 codes (e.g.
F30–F39.9). Three- and four-character ICD10 codes
were projected to a GBD category only if it was totally
included in an unique GBD category. For instance, the
ICD10 code P37 could not be projected to a GBD cat-
egory as P37.0 was included in the GBD category
“Tuberculosis”, and P37.3 was included in the GBD
category “Neglected tropical diseases excluding malaria”.
Blocks of ICD10 codes were split into a list of three- and
four-character ICD10 codes (e.g. F30–F39.9 was split into
F30, F31, …, F39.9). The block of ICD10 codes was pro-
jected to the GBD category(ies) corresponding to the indi-
vidual projections of the three- and four-character ICD10
codes. In the example from Fig. 1, the ICD10 codes were
projected to the GBD category “Musculoskeletal disorders”.
Expert-based enrichment
Some UMLS concepts were not mapped to any candidate
GBD category. We manually reviewed those UMLS con-
cepts appearing in more than 10 clinical trials registered at
the WHO ICTRP database by February 2014 and projected
them to candidate GBD categories when relevant. We
manually reviewed 503 UMLS concepts, among which 62
could be projected to candidate GBD categories (Additional
file 1: Datasets S1 and S2). We developed the classifier with
and without the expert-based enrichment.
Prioritization rules for GBD classification
For each trial, the previous stages resulted in several
pathways from the health condition, the public title and
the scientific title fields to multiple candidate GBD cat-
egories, respectively. These pathways may pass through
several UMLS concepts and ICD10 codes. We developed
rules of prioritization to define the GBD classification.
We gave priority to pathways issued from the health
condition field because, by definition, it contains the in-
formation about the health condition(s) studied in the
clinical trial. We also gave priority to candidate GBD
categories for which the trial record was consistently
projected by several pathways versus candidate GBD cat-
egories reached by isolated pathways. This rule aims at
discarding candidate GBD categories that may appear by
noise (Prioritization rules in Additional file 1). We devel-
oped the classifier with and without the rule of giving pri-
ority to the health condition field. In the example from
Fig. 1, all the pathways from the trial record arrived at the
same GBD category, “Musculoskeletal disorders”.
Note that for some trials, the classifier may not find
any GBD category. These trials may study health condi-
tions corresponding to residual categories or health con-
ditions not relevant for the GBD 2010 study (eg, pain
management). These trials were classified as “No GBD”
category trials.
External validation
We compared the automatic classification to a manual
classification (considered the gold standard) for a large
test set of registered clinical trials. We measured the
performance of 8 versions of the classifier, correspond-
ing to the combinations of using or not the WSD server,
using or not the expert-based enrichment, and giving or
not priority to the health condition field.
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Clinical trial data used in our study
The test set included data from 3 different sources. First,
we used data from the Epidemiological Study of Ran-
domized Trials, which selected all primary publications
of clinical trials published in December 2012 and indexed
in PubMed by November 2013 [35]. Among the 1,351 pub-
lications, we identified 519 trials registered at the WHO
ICTRP. Two independent physicians manually classified
Fig. 2 Methodological stages for classification. The classification of clinical trial records has 5 stages. The 4 initial stages allow for deriving pathways from
the clinical trial record to candidate GBD categories: annotation of text from the trial record with UMLS concepts by using MetaMap, projection of UMLS
concepts to ICD10 codes with IntraMap, projection of ICD10 codes to candidate GBD categories, and expert-based enrichment when automatic pathways
are not possible. The fifth stage allows for deriving the GBD classification of the trial based on prioritization rules over the pathways found
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each publication according to GBD categories. Second, we
used data from a WHO study that extracted a random
5 % sample of clinical trials of interventions registered in
the ICTRP by August 2012 [36]. One physician classified
2,381 trial records with GBD categories according to Table
C3 in [37], with consensus with a second physician in case
of ambiguity. We identified 1,271 trial records for which
the classification could be unambiguously mapped to our
grouping of GBD categories. Finally, we used data from an
ongoing study from our team that involves 973 clinical
trials of cancer registered at ICTRP before June 2015. One
physician classified each record according to GBD
categories, with consensus with a second physician in case
of doubt. In total we included 2,763 trials in the external
test set (Test set of clinical trials in Additional file 1).
Evaluation metrics
We assessed the performance of the classifier by measuring
the proportion of trials for which the automatic classifica-
tion corresponded exactly to the gold standard (exact-
matching). We evaluated the exact-matching over trials
concerning a unique GBD category, two or more GBD cat-
egories and no GBD categories. We computed the overall
exact-matching separately for each source of data. We
chose the best version of the classifier according to the
overall exact-matching proportion. For the best version of
the classifier, we evaluated the sensitivities, specificities and
positive predictive values for each GBD category. The posi-
tive predictive value gives the probability that the trial truly
concerned the GBD category identified. If the sensitivity is
high for a GBD category, a negative result rules out the cat-
egory; if the specificity is high, a positive result rules in the
category. We derived the positive and negative likelihood
ratios (LR+ and LR-); we considered that the classifier reli-
ably identified GBD categories when LR+ > 10 (ruling in
the disease), and LR- < 0.1 (ruling out the disease). We
computed the weighted average of the sensitivities and
specificities across categories.
Lastly, to put the performance measures of the
knowledge-based classifier into context, we compared
them to a baseline using a simple method of classifica-
tion. The baseline did not used the UMLS knowledge
source, but a clinical trial record was classified to a GBD
category if at least one of the disease names defining
that GBD category appeared verbatim in the condition
field, the public or scientific titles, separately, or in at
least one of these three text fields (for disease names
used see Table 1 and Web Table 1 in [28]).
Classification of all clinical trials registered in the WHO
ICTRP database
We downloaded all trial records available at the WHO
ICTRP by February 1, 2014. We classified all interven-
tional trials initiated between 2006 and 2012 by applying
the best-performing version of the classifier. We evaluated
the total number of trials mapped to each GBD category.
Research reproducibility
The classifier was coded by using R 3.2.2 (R Development
Core Team, Vienna, Austria). The programs of the classi-
fier is publicly available for the research community to use
at the open source platform github (github.com/iatal/
trial_gbd). It includes all the codes underlying the classifi-
cation of clinical trial records downloaded at the WHO
ICTRP or at clinicaltrials.gov websites towards the 28- or
171-class grouping of GBD categories. In addition, an on-
line interface to optimize manual classification of clinical
trials records registered at the WHO ICTRP is available at
(http://www.clinicalepidemio.fr/gbd_study_who/). Finally,
the classification using the best-performing version of
the classifier is provided for all interventional trials
registered at WHO ICTRP (N = 109,603 trials by February
2014, Additional file 2).
Results
Among 2,763 trials in the external test set, 2,328
(84.3 %) concerned a single GBD category, 28 (1.0 %) 2 or
more GBD categories, and 407 (14.7 %) residual categories
or health conditions not relevant in the GBD 2010 study.
Many clinical trials studied “Neoplasms” (958 trials),
followed by “Diabetes, urinary diseases and male infertility”
(242 trials) and “Cardiovascular and circulatory diseases”
(235 trials) (Table 2 and Additional file 1: Table S2).
Process of classification of trials
We describe how the classifier performed on the exter-
nal test set (see Additional file 1 for the process of classi-
fication according to the 171 GBD categories).
Pathways from trial records to candidate GBD categories
MetaMap annotated 2,600/2,763 (94.1 %) of the trials with
at least one UMLS concept. The median (Q1, Q3) number
of UMLS concepts per trial was 3 (3, 5) when using the
WSD server and 4 (3, 6) without the WSD server.
The annotation of all trials involved 2,180 different UMLS
concepts. IntraMap projected 1,995/2,180 (91.5 %) UMLS
concepts. The median (Q1, Q3) number of ICD10 codes
per UMLS concept was 2 (1, 2). The UMLS concepts
were projected to 1,361 different ICD10 codes and
1,034/1,361 (76.0 %) ICD10 codes were projected to
at least one GBD category.
At this stage, 573/2,180 (26.3 %) UMLS concepts
could not be projected to a GBD category. The expert-
based enrichment allowed for projecting an additional
41/573 (7.2 %) UMLS concepts.
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GBD classification
Depending on the version of the classifier, between 594
(21.5 %) and 648 trials (23.5 %) had several candidate
GBD categories. With the rule giving priority to the
health condition field, the number of trials actually clas-
sified with several GBD categories ranged from 177
Table 2 Distribution of the external test set (n = 2,763 trials) across the 28-class grouping of the GBD cause list, performance of the
best performing version of the classifier in the external test set, and projection of all trials in the WHO ICTRP database (n = 109,603)
External test set WHO ICTRP
GBD categories No.
trials
Sen (%) Spe (%) PV+ (%) LR+ LR- No. trials (%)
Neoplasms 958 97.4 [96.7-97.7] 97.5 [97.0-97.7] 95.3 [94.4-95.8] 38.2 [28.7-50.8] 0.03 [0.02-0.04] 25,004 (22.8)
Diabetes, urinary diseases
and male infertility
242 81.0 [78.0-83.0] 97.4 [97.0-97.7] 75.1 [72.1-77.4] 31.4 [24.5-40.2] 0.20 [0.15-0.25] 9,749 (8.9)
Cardiovascular and
circulatory diseases
235 75.7 [72.5-78.1] 97.6 [97.2-97.9] 74.8 [71.6-77.2] 31.9 [24.6-41.4] 0.25 [0.20-0.31] 8,906 (8.1)
Mental and behavioral
disorders
143 93.7 [90.5-94.7] 98.7 [98.4-98.9] 80.2 [76.5-82.6] 74.4 [52.9-104.7] 0.06 [0.03-0.12] 7,609 (6.9)
Musculoskeletal disorders 113 88.5 [84.2-90.3] 98.5 [98.2-98.7] 71.4 [67.1-74.6] 58.6 [42.8-80.3] 0.12 [0.07-0.19] 6,112 (5.6)
HIV/AIDS 97 88.7 [83.9-90.4] 99.7 [99.6-99.8] 92.5 [88.0-93.6] 337.7 [160.6-710.0] 0.11 [0.07-0.20] 2,295 (2.1)
Neurological disorders 93 84.9 [79.9-87.3] 98.5 [98.2-98.7] 66.4 [61.6-70.1] 56.7 [41.2-78.0] 0.15 [0.09-0.25] 6,355 (5.8)
Chronic respiratory diseases 81 93.8 [89.0-94.6] 99.4 [99.1-99.5] 81.7 [76.5-84.4] 148.0 [91.9-238.5] 0.06 [0.03-0.15] 4,104 (3.7)
Sense organ diseases 56 92.9 [86.5-93.7] 98.5 [98.2-98.7] 56.5 [51.2-61.3] 62.8 [45.8-86.2] 0.07 [0.03-0.19] 3,461 (3.2)





49 81.6 [73.9-84.8] 99.2 [99.0-99.3] 65.6 [58.7-70.6] 105.5 [67.5-164.8] 0.19 [0.10-0.33] 3,200 (2.9)
Maternal disorders 43 39.5 [33.2-47.6] 99.8 [99.7-99.8] 77.3 [64.7-81.7] 215.1 [83.1-556.4] 0.61 [0.48-0.77] 602 (0.5)
Digestive diseases
(except cirrhosis)
32 75.0 [65.0-79.7] 99.0 [98.7-99.1] 46.2 [39.7-53.1] 73.2 [48.1-111.3] 0.25 [0.14-0.46] 4,454 (4.1)
Cirrhosis of the liver 23 82.6 [70.2-85.6] 99.4 [99.2-99.5] 52.8 [44.6-60.4] 133.1 [80.0-221.6] 0.17 [0.07-0.43] 1,412 (1.3)
Congenital anomalies 23 95.7 [78.1-99.9] 98.8 [98.5-98.9] 39.3 [33.7-46.3] 77.1 [54.6-108.9] 0.04 [0.01-0.30] 1,947 (1.8)
Skin and subcutaneous
diseases
22 81.8 [69.1-85.1] 99.1 [98.9-99.2] 42.9 [36.1-50.8] 93.4 [59.9-145.7] 0.18 [0.08-0.45] 3,652 (3.3)
Hepatitis 17 82.4 [67.5-85.3] 99.9 [99.7-99.9] 77.8 [63.7-82.1] 565.4 [207.2-1542.5] 0.18 [0.06-0.49] 1,082 (1.0)
Tuberculosis 16 87.5 [71.9-88.5] 99.9 [99.8-99.9] 87.5 [71.9-88.5] 1201.8 [297.0-4862.5] 0.13 [0.03-0.46] 306 (0.3)
Nutritional deficiencies 16 68.8 [54.6-75.7] 99.5 [99.2-99.5] 42.3 [34.2-52.4] 125.9 [68.9-230.1] 0.31 [0.15-0.65] 1,226 (1.1)
Hemoglobinopathies and
hemolytic anemias
16 62.5 [49.1-71.0] 99.9 [99.7-99.9] 71.4 [55.9-77.8] 429.2 [150.2-1226.9] 0.38 [0.20-0.71] 360 (0.3)
Malaria 14 100.0 [78.5-100.0] 100.0 [99.9-100.0] 93.3 [68.1-99.8] 2749.0 [387.4-19508.4] - 442 (0.4)
Gynecological diseases 11 81.8 [62.7-84.4] 99.6 [99.4-99.7] 47.4 [37.4-58.3] 225.2 [114.2-443.8] 0.18 [0.05-0.64] 1,536 (1.4)
Neonatal disorders 10 40.0 [29.5-56.0] 99.7 [99.6-99.8] 36.4 [27.3-52.5] 157.3 [54.5-454.1] 0.60 [0.36-1.00] 718 (0.7)
Oral disorders 8 37.5 [27.3-55.8] 99.9 [99.7-99.9] 42.9 [30.3-60.5] 258.3 [68.6-973.0] 0.63 [0.37-1.07] 576 (0.5)
Neglected tropical diseases
excluding malaria
7 85.7 [42.1-99.6] 100.0 [99.9-100.0] 100.0 [61.0-100.0] - 0.14 [0.02-0.88] 361 (0.3)
Leprosy 2 100.0 [15.8-100.0] 100.0 [99.9-100.0] 66.7 [38.7-76.0] 2761.0 [389.1-19593.6] - 74 (0.1)
Sexually transmitted
diseases excluding HIV
1 0.0 [0.0-97.5] 99.8 [99.7-99.8] 0.0 [0.0-43.4] - - 187 (0.2)
Sudden infant death
syndrome
0 - 100.0 [99.9-100.0] - - - 5 (0.0)
No GBD category 407 53.1 [50.6-55.5] 92.9 [92.3-93.4] 56.4 [53.8-58.9] 7.5 [6.3-8.9] 0.51 [0.46-0.56] 22,450 (20.5)
Sen Sensitivity, Spe specificity, PV+ positive predictive value, LR+ positive likelihood ratio, LR- negative likelihood ratio. The version of the classifier used was: using
the Word Server Disambiguation server, the expert-based enrichment, and giving priority to the health condition field
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(6.4 %) to 184 (6.7 %). Without the rule of giving priority
to the health condition field, this number ranged from
244 (8.8 %) to 253 (9.2 %). Across all versions of the
classifier, the number of trials without GBD classification
ranged from 377 (13.6 %) to 414 (15.0 %).
Evaluation of the classifier
Overall performance
The performance of the 8 versions of the classifier is
shown in Table 3. The exact-matching proportion was
similar for all versions of the classifier. However, the best
performance was achieved by using the WSD server,
expert-based enrichment, and giving priority to the
health condition field (77.8 % of exact-matching). The
exact-matching proportion was larger for trials concerning
a unique GBD category (82.7 %) and lowest for trials con-
cerning two or more GBD categories (28.6 %). The best
version of the classifier was the same for the 171 GBD
categories (Additional file 1: Table S3). The performance
varied across data sources; overall exact-matching ranged
from 66.7 % to 82.2 % (Table 4). When classifying trial re-
cords without using the UMLS knowledge source but only
using disease names defining the GBD categories, the pro-
portion of clinical trial records from the test set correctly
classified to GBD categories was of 51.8 % (Table 3). The
knowledge-based classifier had sensitivity and specificity
29.6 % and 5.4 % higher as compared to the baseline not
using the UMLS knowledge source.
Performance for each GBD category
The performance of the best-performing classifier to iden-
tify the “Neoplasms” category was excellent (Table 2). The
positive likelihood ratio was 38.2 [28.7–50.8] and negative
likelihood ratio 0.03 [0.02–0.04]; we can be confident that
trials classified as studying “Neoplasms” actually concerned
that GBD category, and conversely those not classified as
studying “Neoplasms” did not concern the category.
The performance of the classifier in identifying the
“Diabetes, urinary diseases and male infertility” and
“Cardiovascular and circulatory diseases” categories was
good. The specificity of these categories was very high,
so a mapping of these categories based on the classifier
will not overestimate the effort of research in these
fields. However, the sensitivity for these categories was
81.0 % [78.0–83.0] and 75.7 % [72.5–78.1], respectively,
so a mapping of these categories may underestimate the
effort of research in these fields.
The performance of the classifier in identifying the
“Mental and behavioral disorders”, “Musculoskeletal disor-
ders”, “HIV/AIDS” and “Neurological disorders” categor-
ies was high. These categories also had high positive
likelihood ratios and low negative likelihood ratios. How-
ever, the numbers of trials concerning these categories
were lower. We cannot conclude on the performance in
identifying the remaining GBD categories because of the
very low numbers of trials in the external test set (<90 tri-
als per category).





















1 Yes Yes Yes 77.8 82.7 28.6 53.1 81.9 97.4
2 Yes Yes No 77.5 82.5 28.6 52.1 81.8 97.4
3 Yes No Yes 76.9 81.4 28.6 54.8 81.0 97.2
4 Yes No No 76.9 81.5 28.6 53.8 81.1 97.2
5 No Yes Yes 75.6 80.1 28.6 53.1 81.9 97.0
6 No Yes No 75.3 79.9 28.6 52.1 81.8 97.0
7 No No Yes 74.8 79.0 25.0 54.8 81.0 96.9
8 No No No 74.8 79.1 25.0 53.8 81.2 96.9
Baselines Condition field 48.7 40.5 10.7 98.5 49.3 91.4
Public title 38.1 27.6 7.1 100.0 38.2 89.6
Official title 38.0 27.6 7.1 99.3 38.2 89.6
Three text fields 51.4 43.7 17.9 97.8 52.3 92.0
Exact-matching and weighted averaged sensitivities and specificities for 8 versions of the classifier for the 28 GBD categories, compared to the baseline.
Exact-matching corresponds to the proportion (in %) of trials for which the automatic GBD classification is correct. Exact-matching was estimated over all trials
(N = 2,763), trials concerning a unique GBD category (N = 2,328), trials concerning 2 or more GBD categories (N = 28), and trials not relevant for the GBD (N = 407).
The weighted averaged sensitivity and specificity corresponds to the weighted average across GBD categories of the sensitivities and specificities for each GBD
category plus the “No GBD” category (in %). The 8 versions correspond to the combinations of the use or not of the Word Sense Disambiguation server during
the text annotation, the expert-based enrichment database, and the priority to the health condition field as a prioritization rule. The baseline did not used the
UMLS knowledge source, but a clinical trial record was classified to a GBD category if at least one of the disease names defining that GBD category appeared
verbatim in the condition field, the public or scientific titles, separately, or in at least one of these three text fields
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The lowest performance was for the “Injuries” and
“Maternal disorders” categories. The “Injuries” category
was studied by 56 clinical trials and the sensitivity was
low (16.1 % [13.4–23.1]), so a high proportion of trials
concerning injuries may not be detected by the classifier.
Similarly, the sensitivity for “Maternal disorders” was
39.5 % [33.2–47.6], so the classifier may not detect cor-
rectly these trials.
Overall, our classifier identified 407 trials not concerning
any GBD category. The sensitivity was low (53.1 % [50.6–
55.5]), so half of the trials not concerning any relevant
GBD category were actually classified by using GBD cat-
egories. The positive predictive value was also low (56.4 %
[53.8–58.9]), so half of trials classified as “No GBD” cat-
egory actually concerned a relevant GBD category.
When classifying trial records without using the UMLS
knowledge source but only using disease names defining
the GBD categories, the sensitivities were extremely
low as compared to those of the knowledge-based
classifier for all GBD categories but for semantically
simple GBD categories: “HIV/AIDS”, “Hepatitis”, “Tu-
berculosis”, “Malaria” and “Leprosy” (Additional file 1:
Table S4).
Across the 171 GBD categories, the performance
was appropriate for the GBD categories most repre-
sented in the test set. However, for a high proportion
of GBD categories, the number of trials in the test
set was not sufficient to conclude on the performance
of the classifier in identifying them (Additional file 1:
Table S2).
Classification of all trials registered at the WHO ICTRP
In total, 109,603 interventional trials were classified
by using the best-performing version of the classifier
(Additional file 2). The number of trials per GBD category
is shown in Table 2. The “Neoplasms” category was the
most used for classifying clinical trials (22.8 %), followed
by “Diabetes, urinary diseases and male infertility” (8.9 %)
and “Cardiovascular and circulatory diseases” (8.1 %). In
total, 20.5 % of trials could not be classified by a relevant
GBD category.
Discussion
We developed a knowledge-based classifier to automat-
ically map clinical trial records to a 28- and 171-class
grouping of the taxonomy of diseases and injuries from
the GBD 2010 study. In a validation study, the perform-
ance of the classifier was very good for trials of major
groups of diseases, including cancer, diabetes and cardio-
vascular diseases. Our classifier allowed for classifying all
trials registered at the WHO ICTRP.
Comparison to related work
Several studies have previously evaluated the gap be-
tween health research and health needs [35, 36, 38–43].
However, in these studies, the classification of health
R&D activities was always conducted manually. Manual
classification inherently restricted those studies to lim-
ited sample sizes, specific medical areas, regions or types
of studies. In addition, these studies were not updated.
Our automatic classifier can allow for large-scale map-
ping of all clinical trials registered at the WHO ICTRP
(more than 300,000 trials) about all diseases and all re-
gions and the evolution over time.
Previous work used NLP methods to conduct curation
of the eligibility criteria field from clinical trial records
to improve the retrieval of relevant clinical trials for pa-
tients [14–26] In contrast to previous work, we con-
ducted NLP analyses of the condition field and the
public and scientific titles from clinical trial records to
achieve a different objective, the classification of the
condition studied in clinical trials according to a stan-
dardized taxonomy of diseases and injuries. Previous
studies of automatic indexing used health topics in med-
ical research. The Medical Text Indexer (MTI), devel-
oped at the NLM, is used for providing indexing
recommendations for data sources such as MEDLINE,
PubMed and ClinicalTrials.gov. [29, 44] MTI produces
Medical Subject Headings (MeSH) recommendations by
combining a statistical method and a natural language
processing method based on MetaMap and the Restrict-
to-MeSH implemented in IntraMap. This algorithm was
shown to be successful for automatically assigning ICD9
Table 4 Performance of the classifier per source of data for the 28 GBD categories
Exact-matching (% n/N) Weighted average across 28 GBD categories
Source All trials One GBD category No GBD category Two or more GBD
categories
Sensitivity Specificity
Emdin 2015 66.7 (346/519) 66.4 (300/452) 68.2 (45/66) 100.0 (1/1) 71.5 96.4
Viergever 2013 82.2 (1045/1271) 85.3 (925/1085) 64.5 (120/186) 0.0 (0/0) 86.6 97.8
On going work 77.9 (758/973) 88.5 (700/791) 32.9 (51/155) 25.9 (7/27) 81.3 97.2
Exact-matching and weighted averaged sensitivities and specificities for the classifier to the 28 GBD categories for each source of data. The version of the classifier used
was: using the Word Sense Disambiguation server, the expert-based enrichment database and the priority to the health condition field. Exact-matching corresponds to
the proportion (in %) of trials for which the automatic GBD classification is correct. Exact-matching was estimated over all trials, trials concerning a unique GBD category,
trials concerning 2 or more GBD categories, and trials not relevant for the GBD. The weighted averaged sensitivity and specificity corresponds to the weighted average
across GBD categories of the sensitivities and specificities for each GBD category plus the “No GBD” category (in %)
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codes to radiology reports [45]. To our knowledge no
previous work has used the knowledge-based sequence
MetaMap - IntraMap to assign GBD categories to clin-
ical trials. The Aggregate Analysis of ClinicalTrials.gov
project used indexing with MeSH terms to group trials
by medical specialty [30]. However, the medical special-
ties cannot be connected to the burden of disease. Evans
et al. projected all articles indexed in MEDLINE to GBD
categories based on indexing publications with MeSH
terms from the MTI [46]. The authors linked MeSH
terms to ICD9 codes by using the UMLS database. In
our work, we directly targeted a classification of texts
from trial records by using ICD10 codes because GBD
categories are defined with that terminology. Instead of
using MeSH terms as an intermediate for projection,
which may increase the error rate, we chose to develop
our method for classifying automatically health topics
according to GBD categories based on ICD10. In
addition, we mapped ICD10 codes to GBD categories
because the GBD 2010 study provides a burden estimate
for each GBD category, and not for each ICD10 code.
Moreover, these previous studies focused on the cur-
ation of health topics of clinical trials records registered
at ClinicalTrials.gov, thereby excluding 31.2 % of trials in
the WHO ICTRP [9]. Our method of classification was
based on the processing of the condition field and public
and scientific titles only, which are required by the
WHO ICTRP [47]. Thus, our method can be transposed
to any of the 16 clinical trial repositories included in the
WHO ICTRP up to date, including clinicaltrials.gov. All
these sources of registries are fundamental to conduct a
worldwide mapping of registered clinical trials to be
compared to global health needs. In addition, in our
github repository we include codes to analyze clinical
trial records downloaded from WHO ICTRP and clini-
caltrials.gov websites.
Strength of the knowledge-based classifier
Our classifier has several strengths. First, it allows for
developing a reliable region-specific mapping of trials,
especially in fields such as cancer. Such a mapping can
be compared to the region-specific burden of the corre-
sponding diseases. Considering that the classification is
imperfect, a region-specific mapping of research topics
other than cancer with the classifier should take into ac-
count the possible misclassification. Second, the classi-
fier of clinical trials we developed may be used for
conducting semi- and fully-automatic classification rec-
ommendations. Machine learning methods based on the
characteristics of trial records and on the pathways
drawn between trials and GBD categories may allow for
identifying trials for which the classifier does not show a
confident classification. These trials may be considered
for manual revision. Because the WHO ICTRP database
is large and constantly growing, manual revisions may
be expensive. Crowd-sourcing based on the interface for
the manual classification we developed could be scaled
up to divide the effort needed for revision. In addition,
trial registries such as ClinicalTrials.gov could include
the GBD classification as a mandatory field in trial re-
cords. The classifier we developed could provide an
automatic recommendation for classification of newly
registered trials by the GBD categories, thus reducing
the burden of registration. Another strength of the clas-
sifier is that it is based on the UMLS Knowledge Source,
a metathesaurus widely used for analyzing biomedical
text, which increases the portability and reproducibility
of the classification. The classification method develop-
ment did not rely on data in the test set. Other ap-
proaches such as statistical methods of classification (e.g.
support vector machines) may be used to address our
objective. However, our knowledge-based classifier may
be more resilient to the evolution of clinical trial re-
cords. Every year, about 20,000 new clinical trials are
registered at WHO ICTRP [9]. Statistical methods of
classification would need new training data to perform
classification out of the rule space of a training dataset.
Another strength is that our knowledge-based classifier
allows understanding the process of classification of trial
records (Fig. 1), as compared to statistical classifiers. For
a public health project, it is of great value understanding
the process of data curation [48, 49]. In addition, the ap-
proach is generalizable to other sources such as grants,
articles, and systematic reviews.
Performance of the knowledge-based classifier
The evaluation of our classifier on a gold standard exter-
nal test set yielded an overall performance of 81.9 % sen-
sitivity and 97.6 % specificity. Overall, 77.8 % of trial
records from the external test set were correctly classi-
fied towards a 28-class grouping of the GBD cause list.
Pradhan et al. evaluated the performance of 17 systems
to normalize disorder mentions in biomedical text using
a standardized ontology, the Systematized Nomenclature
of Medicine—Clinical Terms (SNOMED CT) [50, 51].
In that study, the best performing system correctly nor-
malized 58.9 % of disorder mentions. It is hard to com-
pare this performance to the performance of our
classifier, as the input space (biomedical text vs clinical
trial records) and the target spaces (SNOMED CT vs
GBD categories) differ. However, we consider that the
performance of the classifier was satisfactory for trials
concerning majors groups of diseases as cancer, diabetes
and cardiovascular diseases. In particular, we can be
confident on the mapping provided by the classifier of clin-
ical trials concerning cancer. In addition, the classifier may
not overestimate the effort of research in diabetes and car-
diovascular diseases. Our classifier performed differently
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across data sources. This may be explained because the dif-
ferent these data sources can not be considered as random
samples of clinical trials. However, we could identify some
GBD categories for which the overall performance of the
classifier was excellent.
Limitations
Our work has several limitations. First, the quality of the
mapping of health research depends on the quality of
the registration of clinical trials. Trial registration re-
mains of low quality, but endorsements from WHO are
attempting to improve the registration system [7, 47]. In
addition, the misclassification of diseases may be corre-
lated to trial location. For instance, our classifier only
supports English language, as MetaMap identifies UMLS
concepts in biomedical text written in English. This may
increase the misclassification in non-English speaking
countries. However, according to the International Stan-
dards for Clinical Trial Registries from the WHO, all
items of trial records included in the WHO ICTRP (in-
cluding the condition field and the public and scientific
titles) must be available in English language [47]. Simi-
larly, compliance to registration of clinical trials may
vary across regions. However, it is unlikely that compli-
ance on registration vary across diseases. Therefore, in
regions with low compliance of registration, a lower
number of clinical trials concerning a disease as com-
pared to other diseases may effectively correspond to a
gap of health research. Second, our classifier may poorly
identify some categories. For instance, the sensitivity for
the “Injuries” category, accounting for 10.7 % of the glo-
bal burden in 2010, was low [27]. In our test set, clinical
trials concerning injuries mainly studied the adverse ef-
fects of medical treatments (35/56). In these trials, the
classifier is more likely to identify the health condition
targeted by those medical treatments rather than consid-
ering that the clinical trials studied the adverse effects of
the treatments. Thus, this misclassification may not be
considered an error in the mapping because trials study-
ing the adverse effects of the treatment used for a cer-
tain condition will be conducted in countries where that
particular condition is a burden. Third, the classifier
may poorly identify trials not concerning any relevant
GBD category. For the classifier to identify a “No GBD”
category trial, it needs to be unable to project the trial to
any GBD category. However, any UMLS concept recog-
nized in the trial record projected to a GBD category will
lead to a classification of the trial. The suppression of
noise candidate GBD categories by using the prioritization
rules do not allow for suppressing all the candidate GBD
categories but rather only choosing the most accurate
classification among the candidates. However, the specific-
ities of each of the 28 GBD categories were generally high,
so the number of “No GBD” category trials wrongly classi-
fied remained low per GBD category.
In our 28-class grouping of diseases and injuries we
excluded two residual categories from the GBD cause
list, “Other infectious diseases” and “Other endocrine,
nutritional, blood, and immune disorders”, accounting
for 1.2 % of the global burden in 2010. These residual
categories are difficult to cover as they are defined using
sets of ICD10 to complement the major diseases groups,
and are thus particularly large and complex. We decided
no to take into account these categories because these
coverings may add much complexity to the classification
tasks with very small benefits in terms of global mapping
of clinical research. Actually, we considered that these
categories would not be informative for the purposes of
developing a global mapping of registered clinical trials
across diseases to be compared to health needs. Finally,
in our study, we considered the particular taxonomy of
the US Institute for Health Metrics and Evaluation for
the GBD 2010 Study. This taxonomy may not be per-
fectly suitable for conducting a mapping of health R&D.
For instance, health conditions that may be considered
public health priorities in some regions, such as obesity,
venous thromboembolism or heart failure, are part of
the residual categories. However, the GBD study is a
worldwide effort to estimate the evolution of the burden
of all diseases in all countries in the world. It provides a
consensual taxonomy of diseases for use in comparing
the research effort to the burden of diseases.
Conclusion
Herein, we presented a knowledge-based classifier to
map the health conditions studied in registered clinical
trials according to the taxonomy of diseases and injuries
from the Global Burden of Diseases 2010 study. The
overall performance of the classifier was 81.9 % sensitiv-
ity and 97.6 % specificity. We applied it to the entire
WHO ICTRP database, which characterizes the global
burden of disease addressed by the 109,603 clinical trials
in the database. This classifier allows for comparing the
research effort to the disease burden on a large scale for





Additional file 1: Includes details on the implementation of MetaMap
and IntraMap, prioritization rules, the test set of clinical trials and the
classification of the external test set according to the 171 GBD categories.
Dataset S1: Expert-based enrichment database for the classification
according to the 28 GBD categories. Manual classification of 503 UMLS
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concepts that could not be mapped to any of the 28 GBD categories.
Dataset S2: Expert-based enrichment database for the classification
according to the 171 GBD categories. Manual classification of 655 UMLS
concepts that could not be mapped to any of the 171 GBD categories,
among which 108 could be projected to candidate GBD categories.
Table S1: Excluded residual GBD categories for the grouping of the GBD
cause list in 171 GBD categories. A grouping of 193 GBD categories was
defined during the GBD 2010 study to inform policy makers about the
main health problems per country. From these 193 GBD categories, we
excluded the 22 residual categories listed in the Table. We developed a
classifier for the remaining 171 GBD categories. Among these residual
categories, the unique excluded categories in the grouping of 28 GBD
categories were “Other infectious diseases” and “Other endocrine,
nutritional, blood, and immune disorders”. Table S2: Per-category
evaluation of performance of the classifier for the 171 GBD categories
plus the “No GBD” category. Number of trials per GBD category from the
test set of 2,763 clinical trials. Sensitivities, specificities (in %) and likelihood
ratios for each of the 171 GBD categories plus the “No GBD” category for
the classifier using the Word Sense Disambiguation server, the expert-based
enrichment database and the priority to the health condition field. Table
S3: Performance of the 8 versions of the classifier for the 171 GBD categories.
Exact-matching and weighted averaged sensitivities and specificities for
8 versions of the classifier for the 171 GBD categories. Exact-matching
corresponds to the proportion (in %) of trials for which the automatic
GBD classification is correct. Exact-matching was estimated over all trials
(N = 2,763), trials concerning a unique GBD category (N = 2,092), trials
concerning 2 or more GBD categories (N = 187), and trials not relevant
for the GBD (N = 484). The weighted averaged sensitivity and specificity
corresponds to the weighted average across GBD categories of the
sensitivities and specificities for each GBD category plus the “No GBD”
category (in %). The 8 versions correspond to the combinations of the
use or not of the Word Sense Disambiguation server during the text
annotation, the expert-based enrichment database, and the priority to
the health condition field as a prioritization rule. Table S4: Per-category
evaluation of the performance of the baseline for the 28 GBD categories
plus the “No GBD” category. Number of trials per GBD category from the
test set of 2,763 clinical trials. Sensitivities and specificities (in %) of the
28 GBD categories plus the “No GBD” category for the classification of
clinical trial records towards GBD categories without using the UMLS
knowledge source but based on the recognition in free text of the
names of diseases defining in each GBD category only. For the baseline
a clinical trial records was classified with a GBD category if at least one
of the 291 disease names from the GBD cause list defining that GBD
category appeared verbatim in the condition field, the public or scientific
titles, separately, or in at least one of these three text fields. (DOCX 84 kb)
Additional file 2: Classification towards the 28-class grouping of GBD
categories of all interventional trials registered at WHO ICTRP before February
2014. Classification of N = 109,603 clinical trials using the best-performing
version of the classifier (using the Word Sense Disambiguation server, the
expert-based enrichment database and the priority to the health condition
field. (XLSX 12447 kb)
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